Skip to content
OpenCapital
Get started

Arcus Biosciences RCUS Business Segments — Partnership reimbursements

Similar metrics at other companies

Regeneron Pharmaceuticals logo
REGNReportable Segment — Reimbursement of research and development expenses by collaborators
-$33.6M+9.9%
Viridian Therapeutics, Inc. logo
VRDNReportable Segment — Segment research and development expense
$71.74M+1.0%
Urban Edge Properties logo
UEReportable Segment — Rental revenue from tenant expense reimbursements
$121.41M+5.7%
BGC Group, Inc. logo
BGCReportable Segment — Fees from related parties
$4.3M-2.8%
Zymeworks logo
ZYMEReportable Segment — Other research and development expense
$5.63M+3.1%
InterDigital logo
IDCCReporting Segment — Revenue share costs
$27.5M+938%

Other financials

Income statement

See full
Revenue$17.0M-39.3%
Operating income-$134.0M-9.8%
Net income-$128.0M-14.3%
EPS (diluted)-$1.02+10.5%

Balance sheet

See full
Cash & equivalents$201.0M+4.7%
Total debt$113.0M+88.3%
Total equity$524.0M-1.3%
Total assets$997.0M-13.8%

Cash flow

See full
Operating cash flow-$138.0M-4.5%
CapEx--100%
Free cash flow-$138.0M-3.8%

Valuation

See full
Market cap$3.62B+226%
Enterprise value$3.53B+275%
P/S15.4×+7.5×

Profitability

See full
Operating margin-168.6%-52.7pp
Net margin-156.4%-47.5pp
FCF margin-207.2%—

Returns & leverage

See full
Return on equity-70%+8.4pp
Debt / equity0.2×+0.1×
Current ratio4×-1.3×

Where this comes from

Reported directly by Arcus Biosciences in its filing.

Tagged under the XBRL concept rcus:PartnershipReimbursements.

The official record: Arcus Biosciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arcus Biosciences's business segments — partnership reimbursements.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Arcus Biosciences's business segments — partnership reimbursements?
Arcus Biosciences (RCUS) reported business segments — partnership reimbursements of -$19M in Q1 2026.
How has Arcus Biosciences's business segments — partnership reimbursements changed year-over-year?
Arcus Biosciences's business segments — partnership reimbursements increased by 50.0% year-over-year, from -$38M to -$19M.
What is the long-term trend for Arcus Biosciences's business segments — partnership reimbursements?
Over 3 years (2022 to 2025), Arcus Biosciences's business segments — partnership reimbursements has grown at a -7.8% compound annual growth rate (CAGR), from -$162M to -$127M.
What does business segments — partnership reimbursements mean?
Represents the portion of development costs recovered from strategic partners or collaborators under shared-risk agreements. This metric is a critical indicator of the company's ability to leverage external funding to offset the high costs of clinical development.